MA
ADAP

MYDA Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

MYDA Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-19,009
Closed -$213K – 143
2018
Q1 		$213K Buy
+19,009
New +$166K 0.15% 98

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MYDA Advisors's ADAP Position: Q2 2018 in Review

MYDA Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2018, closing a stake of 19,009 shares — an estimated $213K sold.

MYDA Advisors first reported a position in ADAP in Q1 2018 and held it in 1 quarter. The position peaked at $213K in Q1 2018. 86 funds tracked by Wall St. Rank hold ADAP as of Q2 2018.

  • MYDA Advisors reported no remaining Adaptimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
  • MYDA Advisors sold 19,009 Adaptimmune Therapeutics shares in Q2 2018, an estimated $213K.
  • MYDA Advisors first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 1 quarter.
  • MYDA Advisors's Adaptimmune Therapeutics position peaked at $213K in Q1 2018.
  • 86 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2018.

Based on MYDA Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.